Literature DB >> 9895272

Pneumolysin in pneumococcal adherence and colonization.

J B Rubins1, A H Paddock, D Charboneau, A M Berry, J C Paton, E N Janoff.   

Abstract

The universal and highly conserved production of pneumolysin, the major pneumococcal cytolysin, among clinical isolates of Streptococcus pneumoniae and the previously reported association of pneumolysin production with increased pneumococcal adherence to respiratory epithelium in organ cultures suggest that this toxin might be important for nasopharyngeal colonization. We confirmed that pneumolysin-deficient mutant pneumococcal strains had decreased adherence to respiratory epithelial cells in vitro compared with their isogeneic wild-type strains. However, neither early nor sustained colonization by type 14 S. pneumoniae in an established murine model was dependent on bacterial production of pneumolysin. We conclude that pneumolysin production is not a major determinant of successful nasopharyngeal colonization by pneumococci. Copyright 1998 Academic Press

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9895272     DOI: 10.1006/mpat.1998.0239

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  19 in total

1.  Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae.

Authors:  D E Briles; E Ades; J C Paton; J S Sampson; G M Carlone; R C Huebner; A Virolainen; E Swiatlo; S K Hollingshead
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

Review 2.  Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review.

Authors:  S Sethi; T F Murphy
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

3.  Decreased virulence of a pneumolysin-deficient strain of Streptococcus pneumoniae in murine meningitis.

Authors:  Andreas Wellmer; Gregor Zysk; Joachim Gerber; Tammo Kunst; Matthias Von Mering; Stefanie Bunkowski; Helmut Eiffert; Roland Nau
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

4.  Upper and lower respiratory tract infection by Streptococcus pneumoniae is affected by pneumolysin deficiency and differences in capsule type.

Authors:  Aras Kadioglu; Sally Taylor; Francesco Iannelli; Gianni Pozzi; Tim J Mitchell; Peter W Andrew
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

5.  Contributions of pneumolysin, pneumococcal surface protein A (PspA), and PspC to pathogenicity of Streptococcus pneumoniae D39 in a mouse model.

Authors:  Abiodun D Ogunniyi; Kim S LeMessurier; Rikki M A Graham; James M Watt; David E Briles; Uwe H Stroeher; James C Paton
Journal:  Infect Immun       Date:  2007-01-29       Impact factor: 3.441

6.  Potential role for ESAT6 in dissemination of M. tuberculosis via human lung epithelial cells.

Authors:  Arvind G Kinhikar; Indu Verma; Dinesh Chandra; Krishna K Singh; Karin Weldingh; Peter Andersen; Tsungda Hsu; William R Jacobs; Suman Laal
Journal:  Mol Microbiol       Date:  2009-11-10       Impact factor: 3.501

7.  Phenotypic characterization of Streptococcus pneumoniae biofilm development.

Authors:  Magee Allegrucci; F Z Hu; K Shen; J Hayes; Garth D Ehrlich; J Christopher Post; Karin Sauer
Journal:  J Bacteriol       Date:  2006-04       Impact factor: 3.490

Review 8.  Hijacking and Use of Host Lipids by Intracellular Pathogens.

Authors:  Alvaro Toledo; Jorge L Benach
Journal:  Microbiol Spectr       Date:  2015-12

9.  Pneumolysin plays a key role at the initial step of establishing pneumococcal nasal colonization.

Authors:  Muneki Hotomi; Jun Yuasa; David E Briles; Noboru Yamanaka
Journal:  Folia Microbiol (Praha)       Date:  2016-01-23       Impact factor: 2.099

10.  Human antibodies to PhtD, PcpA, and Ply reduce adherence to human lung epithelial cells and murine nasopharyngeal colonization by Streptococcus pneumoniae.

Authors:  Ravinder Kaur; Naveen Surendran; Martina Ochs; Michael E Pichichero
Journal:  Infect Immun       Date:  2014-09-22       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.